Bank of America
TCRX icon

Bank of America’s TScan Therapeutics TCRX Stock Holding History

Bank of America’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.1K Buy
57,529
+18,829
+49% +$20.1K ﹤0.01% 5582
2025
Q4 		$38.7K Sell
38,700
-184,324
-83% -$267K ﹤0.01% 5909
2025
Q3 		$406K Buy
223,024
+5,057
+2% +$8.96K ﹤0.01% 5912
2025
Q2 		$316K Buy
217,967
+47,617
+28% +$68.8K ﹤0.01% 5961
2025
Q1 		$235K Buy
170,350
+20,236
+13% +$43.8K ﹤0.01% 6084
2024
Q4 		$456K Buy
150,114
+52,903
+54% +$240K ﹤0.01% 5617
2024
Q3 		$484K Buy
97,211
+53,429
+122% +$322K ﹤0.01% 5503
2024
Q2 		$256K Buy
43,782
+13,603
+45% +$107K ﹤0.01% 5755
2024
Q1 		$240K Sell
30,179
-7,625
-20% -$48K ﹤0.01% 5797
2023
Q4 		$220K Buy
37,804
+37,604
+18,802% +$172K ﹤0.01% 6019
2023
Q3 		$512 Hold
200
– – ﹤0.01% 7307
2023
Q2 		$500 Hold
200
– – ﹤0.01% 7314
2023
Q1 		$420 Sell
200
-34
-15% -$81 ﹤0.01% 7380
2022
Q4 		$362 Buy
+234
New +$574 ﹤0.01% 7471
2022
Q1 		– Sell
-189
Closed -$1K – 8746
2021
Q4 		$1K Buy
+189
New +$1.36K ﹤0.01% 8093

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Bank of America's TCRX Position: Q1 2026 in Review

Bank of America increased its TScan Therapeutics (TCRX) stake by 49% in Q1 2026, buying an estimated $20.1K and bringing the position to 57,529 shares worth $58.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5582.

Bank of America first reported a position in TCRX in Q4 2021 and has held it in 15 quarters since. The position peaked at $484K in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Bank of America held 57,529 shares of TScan Therapeutics worth $58.1K as of Q1 2026.
  • Bank of America bought 18,829 TScan Therapeutics shares in Q1 2026, an estimated $20.1K.
  • TScan Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5582 holding.
  • Bank of America first reported a position in TScan Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Bank of America's TScan Therapeutics position peaked at $484K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.